Navigation Links
ScinoPharm Announces SafeBridge Potent Compound Safety Certification
Date:11/19/2009

TAINAN, Taiwan, Nov. 19 /PRNewswire-Asia/ -- ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), announced that its Tainan facility has received the Potent Compound Safety Certification from SafeBridge(R) Consultants, Inc. The Certification confirms ScinoPharm's competency and proficiency in the safe handling of potent active pharmaceutical ingredients (APIs), and applies to specific laboratories and production areas used for the manufacturing and handling of potent compounds.

ScinoPharm is the first API company in Asia to receive the industry- respected Certification, and joins six other facilities in the United States and Europe actively involved in the SafeBridge Potent Compound Safety Certified program to date.

"The Certification demonstrates our company's commitment to maintaining international standards. Not only are our plants cGMP certified, our stringent enforcement of environmental, health and safety codes are rarities in Asia," said Dr. Jo Shen, President and CEO of ScinoPharm.

The SafeBridge Potent Compound Safety Certification program is the most widely accepted industry benchmark for handling highly potent pharmaceuticals. SafeBridge conducted a 60-element review of programs, procedures, containment and control of the active pharmaceutical ingredients at the company's site. Elements of the program include on-site assessment of the potent compound manufacturing and laboratory areas and the associated equipment, training, toxicology and industrial hygiene support. This third party certification covers facilities, containment equipment, procedures and personnel training concerning potent compound production operations only at ScinoPharm's facility in Tainan, Taiwan.

ScinoPharm has over twelve FDA approved, independent production lines with separate air handling systems. Some of the lines are reserved for non- cytotoxic (lower potency) compounds. Facilities not destined for handling high potency products were not part of the Certification program.

With a cGMP manufacturing facility specifically designed to manufacture cytotoxic and high potency compounds, ScinoPharm can readily handle a range of oncology and hormonal products, as well as most other APIs made of small molecules, peptides and nucleic acids in its other production lines. The company's competency in safely handling of materials spans from early phase clinical supplies to large-scale manufacturing for commercial launches.

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. Combining cost-effective resources and productivity of Asia along with extensive regulatory know-how, ScinoPharm is uniquely positioned to serve global pharmaceutical R&D and manufacturing needs at any level and for any company in this sector. For more information please visit http://www.scinopharm.com .

    Media Contact:

     ScinoPharm Taiwan, Ltd.
     Sabrian Wu
     Tel: +886-6-505-2888 #2867 / +886-920056385
     Email: sabrina.wu@scinopharm.com.tw

SOURCE ScinoPharm Taiwan, Ltd.


'/>"/>
SOURCE ScinoPharm Taiwan, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... July 11, 2017  Bayer has awarded grants totaling more ... part of its prestigious Bayer Hemophilia Awards Program (BHAP). Four ... Philadelphia and Uniformed Services University of the ... the winners. Grant recipients were announced last night during a ... 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston Hotel, ... unparalleled access to global decision makers and innovative biotech ... life science leaders during two impactful days. BioPharm America ... delegates with additional networking opportunities with 4,500+ life science ...
Breaking Medicine Technology:
(Date:7/21/2017)... ORLEANS, La. (PRWEB) , ... July 21, 2017 ... ... to allow 4th-year medical students improve their chances of acceptance to a residency ... for those who have earned degrees outside the U.S. , According to data ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital ... adjustable beds used in such facilities are specially designed to accommodate patients with a ... , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, ...
(Date:7/20/2017)... MD (PRWEB) , ... July 20, 2017 , ... ... company dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary ... million. , Proceeds will be used to complete regulatory submissions and fund final ...
Breaking Medicine News(10 mins):